- Home
- ALTS vs AVTX Comparison
ALTS vs AVTX Comparison
Compare ALTS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- AVTX
- Stock Information
- Founded
- ALTS 1976
- AVTX 2011
- Country
- ALTS United States
- AVTX United States
- Employees
- ALTS N/A
- AVTX N/A
- Industry
- ALTS
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- AVTX Health Care
- Exchange
- ALTS NYSE
- AVTX Nasdaq
- Market Cap
- ALTS 159.4M
- AVTX 57.4M
- IPO Year
- ALTS N/A
- AVTX 2015
- Fundamental
- Price
- ALTS $7.57
- AVTX $4.88
- Analyst Decision
- ALTS
- AVTX Strong Buy
- Analyst Count
- ALTS 0
- AVTX 7
- Target Price
- ALTS N/A
- AVTX $31.00
- AVG Volume (30 Days)
- ALTS 296.4K
- AVTX 97.2K
- Earning Date
- ALTS 08-18-2025
- AVTX 08-11-2025
- Dividend Yield
- ALTS N/A
- AVTX N/A
- EPS Growth
- ALTS N/A
- AVTX N/A
- EPS
- ALTS N/A
- AVTX N/A
- Revenue
- ALTS $18,046,000.00
- AVTX $441,000.00
- Revenue This Year
- ALTS $185.91
- AVTX N/A
- Revenue Next Year
- ALTS $64.93
- AVTX N/A
- P/E Ratio
- ALTS N/A
- AVTX N/A
- Revenue Growth
- ALTS N/A
- AVTX N/A
- 52 Week Low
- ALTS $1.29
- AVTX $3.39
- 52 Week High
- ALTS $10.95
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- ALTS 42.48
- AVTX 54.21
- Support Level
- ALTS $8.90
- AVTX $4.50
- Resistance Level
- ALTS $10.38
- AVTX $5.00
- Average True Range (ATR)
- ALTS 1.07
- AVTX 0.32
- MACD
- ALTS -0.37
- AVTX 0.03
- Stochastic Oscillator
- ALTS 22.61
- AVTX 62.50
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. The company operates in three operating segments: Fintech: provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, Biotechnology: Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties; Corporate and Others: Corporate and Other segment consists of certain corporate general and administrative costs. Company has revenue from Fintech Segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).